EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn’s Disease: The K-STAR Study

Chang Kyun Lee, Won Moon, Jaeyoung Chun, Eun Soo Kim, Hyung Wook Kim, Hyuk Yoon, Hyun Soo Kim, Yoo Jin Lee, Chang Hwan Choi, Yunho Jung, Sung Chul Park, Geun Am Song und 6 weitere

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae171 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Chang Kyun Lee und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Center for Crohn's and Colitis, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Korea Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study investigated the safety and effectiveness of ustekinumab (UST) in Korean patients with Crohn’s disease (CD).

Methods

Adult patients with CD treated with UST were prospectively enrolled in the K-STAR (Post-MarKeting Surveillance for Crohn’s Disease patients treated with STelARa) study between April 2018 and April 2022. Both the clinical effectiveness and adverse effects of UST therapy were analyzed. Missing data were handled using nonresponder imputation (ClinicalTrials.gov Identifier: NCT03942120).

Results

Of the 464 patients enrolled from 44 hospitals across Korea, 457 and 428 patients (Crohn’s disease activity index ≥150) were included in the safety analysis and effectiveness analysis sets, respectively. At weeks 16 to 20 after initiating UST, clinical response, clinical remission, and corticosteroid-free remission rates were 75.0% (321 of 428), 64.0% (274 of 428), and 61.9% (265 of 428), respectively. At week 52 to 66, clinical response, clinical remission, and corticosteroid-free remission rates were 62.4% (267 of 428), 52.6% (225 of 428), and 50.0% (214 of 428), respectively. Combined effectiveness (clinical response + biochemical response) was achieved in 40.0% (171 of 428) and 41.6% (178 of 428) at week 16 to 20 and week 52 to 66, respectively. Biologic-naïve patients exhibited significantly higher rates of combined effectiveness than biologic-experienced patients (50.3% vs 30.7% at week 16-20, P < .001; 47.7% vs 36.0% at week 52-66, P = .014). No additional benefits were observed with the concomitant use of immunomodulators. Ileal location was independently associated with a higher probability of clinical remission compared with colonic or ileocolonic location at week 52 to 66. Adverse and serious adverse events were observed in 28.2% (129 of 457) and 12.7% (58 of 457), respectively, with no new safety signal associated with UST treatment.

Conclusions

Ustekinumab was well-tolerated, effective, and safe as induction and maintenance therapy for CD in Korea.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabCrohn DiseaseHumansMaleFemaleAdultRemission InductionMiddle AgedProspective StudiesRepublic of KoreaTreatment OutcomeYoung AdultProduct Surveillance, PostmarketingFollow-Up Studies

Stichwörter der Autor:innen

Crohn’s diseaseKoreaeffectivenesssafetyustekinumab

Substanzen

Ustekinumab

Autor:innen und Institutionen

  • Department of Gastroenterology, Center for Crohn's and Colitis, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
  • Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, School of Medicine, Kyungpook National University, Korea.
  • Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.

ORCID-Profile: Byong Duk Ye

Förderung

  • Janssen Korea Ltd

Zitieren

APA

Lee, C. K., Moon, W., Chun, J., Kim, E. S., Kim, H. W., Yoon, H., Kim, H. S., Lee, Y. J., Choi, C. H., Jung, Y., Park, S. C., Song, G. A., Lee, J. H., Jung, E. S., Kim, Y., Jung, S. Y., Choi, J. M., & Ye, B. D. (2025). One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn’s Disease: The K-STAR Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae171

Vancouver

Lee CK, Moon W, Chun J, Kim ES, Kim HW, Yoon H, et al. One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn’s Disease: The K-STAR Study. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae171

BibTeX
@article{Lee2025,
  author = {Lee, Chang Kyun and Moon, Won and Chun, Jaeyoung and Kim, Eun Soo and Kim, Hyung Wook and Yoon, Hyuk and Kim, Hyun Soo and Lee, Yoo Jin and Choi, Chang Hwan and Jung, Yunho and Park, Sung Chul and Song, Geun Am and Lee, Jong Hun and Jung, Eun Suk and Kim, Youngdoe and Jung, Su Young and Choi, Jong Min and Ye, Byong Duk},
  title = {One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn’s Disease: The K-STAR Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae171}
}
Kostenlos starten →